Your session is about to expire
← Back to Search
HOBSCOTCH Program for Epilepsy
N/A
Recruiting
Led By Cam Escoffery, PhD, MPH
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of epilepsy (self-reported by participant), with controlled or uncontrolled seizures
No changes in antiepileptic and antidepressant medication regimen for 1 month, however brief discontinuation of antiepileptic medicine for inpatient video electroencephalogram (EEG) evaluation is acceptable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, months 3, 6, 9, 12
Awards & highlights
Study Summary
This trial is testing whether a home-based self-management program (HOBSCOTCH) can improve quality of life and perceived difficulties in cognitive abilities. The study will also test a new mobile application and extra booster sessions to improve long-term outcomes.
Who is the study for?
This trial is for individuals with epilepsy, who have memory complaints and stable medication regimens. They must be literate, have telephone and internet access, but cannot participate if they have dementia, severe mental disability (IQ less than 70), significant visual impairment, or lack a diagnosis of epilepsy.Check my eligibility
What is being tested?
The study tests the HOBSCOTCH program—a home-based self-management strategy to improve quality of life and cognitive abilities in people with epilepsy. It includes a mobile app and optional booster sessions. Participants are split into two groups: one starts immediately; the other waits six months.See study design
What are the potential side effects?
Since this trial involves a self-management program rather than medication, traditional side effects are not expected. However, participants may experience frustration or stress while learning new problem-solving strategies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have epilepsy with seizures that may or may not be under control.
Select...
My epilepsy or depression medication hasn't changed in the last month.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, months 3, 6, 9, 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, months 3, 6, 9, 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Neuro Quality of Life (Neuro-QOL) Item Bank v2.0 - Cognitive Function Score
Change in Quality of Life in Epilepsy (QOLIE-31) Score
Secondary outcome measures
Change in Adult Epilepsy Self-Management Measurement Instrument (AESMMI-65) Score
Change in Health Care Utilization
Change in Health Confidence Score (HCS)
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: HOBSCOTCH groupExperimental Treatment1 Intervention
Participants in this study arm will receive the HOBSCOTCH intervention immediately.
Group II: Wait-listed controlActive Control1 Intervention
Participants in this study arm will be wait-listed for 6 months and will then receive the HOBSCOTCH intervention.
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,635 Previous Clinical Trials
2,559,981 Total Patients Enrolled
8 Trials studying Epilepsy
1,124 Patients Enrolled for Epilepsy
Centers for Disease Control and PreventionFED
875 Previous Clinical Trials
22,477,511 Total Patients Enrolled
7 Trials studying Epilepsy
835 Patients Enrolled for Epilepsy
Cam Escoffery, PhD, MPHPrincipal Investigator - Emory University
Emory University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have trouble seeing well enough to read or write.You have reported problems with your memory.I have never been diagnosed with epilepsy.My epilepsy or depression medication hasn't changed in the last month.I have epilepsy with seizures that may or may not be under control.You have been diagnosed with a memory-related illness like dementia.
Research Study Groups:
This trial has the following groups:- Group 1: HOBSCOTCH group
- Group 2: Wait-listed control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the aggregate number of participants in this trial?
"Affirmative. This clinical trial, which was first listed on March 17th 2021, is actively seeking participants and can be found in the directory of clinicaltrials.gov. 150 patients are necessary to complete this study at one medical centre."
Answered by AI
Are any slots available for participation in this experimentation?
"According to the clinicaltrials.gov website, this medical experiment is actively seeking participants. It was launched on March 17th 2021 and its content has been modified most recently on April 14th 2022."
Answered by AI
What will be the ultimate outcome of this research endeavor?
"This clinical trial spans across Baseline, Months 3, 6, 9 and 12. The primary outcome to be measured is the Change in Quality of Life in Epilepsy (QOLIE-31) Score. Secondary objectives include tracking changes in Adult Epilepsy Self-Management Measurement Instrument (AESMMI-65), Medication Adherence Rating Scale (MARS), as well as Patient Health Questionnaire - 9 Depression (PHQ-9)."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger